Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
Cardiac involvement has been described in Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) infection. Although there are no approved drugs to prevent or treat SARS-CoV-2 infection at present time, several medications used have the potential to increase QT interval and eventually provoke torsades de pointe. The investigators therefore create a study that include all patients with SARS-CoV-2 infection having an electrocardiogram (ECG). The investigators evaluate the percentage of patients with ECG abnormalities, describe the abnormalities and evaluate the occurrence of syncope, ventricular arrhythmia and corrected QT (cQT) interval modification in patients receiving treatment.

Detailed Description
-----------------
In patients with SARS-CoV-2 infection, the investigators analyze baseline ECG as well as follow-up ECG. Patients followed by Bordeaux University Hospital for COVID-19 can be included. ECG are digitized in the computerized patient file (DxCARE) for further analysis.

Official Title
-----------------
Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19

Conditions
-----------------
Arrhythmia, SARS-CoV-2 Infection

Intervention / Treatment
-----------------
* Diagnostic Test: ECG data analysis
* Drug: Treatment data collect
* Biological: Biological check-up data collect
* Other: Collection of clinical events of interest


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of both gender, Followed by Bordeaux University Hospital for SARS-CoV-2 infection with a cardiac monitoring or ECG realized. Non opposition expressed. Exclusion Criteria: Minor, Inability to understand the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SARS-CoV-2 infection<br>This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed. | Diagnostic Test: ECG data analysis<br>* Baseline ECG as well as follow-up ECG are analysed<br>Drug: Treatment data collect<br>* Baseline treatment data as well as follow-up treatment data are collected<br>Biological: Biological check-up data collect<br>* Baseline Biological check-up data as well as follow-up data are collected<br>Other: Collection of clinical events of interest<br>* Clinical events of interest at the baseline as well as follow-up clinical events are collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of ECGs abnormalities in patients SARS-CoV-2 infection | Percentage of ECGs with abnormalities | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution of PR, QRS and cQT interval | The evolution of interval is measured in seconds for patients receiving drugs interfering with cardiac electrophysiology for SARS-CoV-2 infection | Baseline and 1 month | 
| Rate of syncope during treatment | The number of syncope is measured during the treatment | Baseline and 1 month | 
| Rate of cardiac death during treatment | The number of cardiac death is measured during the treatment | Baseline and 1 month | 
| Rate of arrhythmia during treatment | The number of arrhythmia is measured during the treatment | Baseline and 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, ECG, Torsade de pointe, QT interval